If you have been researching ozone-based therapies, you have probably encountered both traditional IV ozone therapy and EBOO therapy, and you have probably found content that presents them as existing on a simple spectrum, with EBOO at the superior end. That framing is understandable from a marketing perspective. From a clinical one, it is incomplete.
Both therapies share a common biochemical foundation. Both involve introducing medical-grade ozone to the bloodstream. And both, when administered appropriately by qualified physicians, have a legitimate place in a well-designed integrative care plan.
But they are procedurally and mechanistically distinct, their evidence bases are not equivalent, and the question of which one is right requires a physician’s assessment, not a preference survey.
This article is written to give patients the clinical context they need before that conversation.
What Is Traditional Ozone Therapy?
Traditional ozone therapy, often called standard ozone therapy, or more precisely, Major Autohemotherapy (MAH), is the foundational form of systemic intravenous ozone treatment. It is the most widely studied ozone protocol in the peer-reviewed literature and the starting point for understanding how ozone works biologically.
The procedure is straightforward. A volume of the patient’s own blood, typically 150 to 200 milliliters, is drawn through a single intravenous access point and collected in a sterile, heparinized container. Medical-grade ozone gas is then introduced into that container, where it contacts and reacts with the blood. The ozonated blood is then reinfused into the patient through the same IV line. A standard session takes approximately 45 to 60 minutes.
Standard ozone therapy is also sometimes performed as a hyperbaric ozone variant, often called 10-pass therapy, in which the blood is cycled through the ozonation chamber multiple times under pressure. This is related to, but distinct from, the standard single-pass MAH protocol.
Who should avoid EBOO therapy?
People with certain medical conditions, active infections, bleeding risks, or specific treatment contraindications may need to avoid EBOO therapy.
How Does Ozone Treatment Work?
Ozone (O₃) is a triatomic form of oxygen. When it contacts the bloodstream, it does not function as a direct antioxidant, which is a common misconception, but rather as a biological signaling agent through a mechanism called oxidative preconditioning.
The reaction between ozone and unsaturated fatty acids in plasma generates hydrogen peroxide (Hâ‚‚Oâ‚‚) and lipid ozonides. These secondary messengers activate the Nrf2 transcription pathway, which upregulates the body’s own antioxidant enzyme systems, including glutathione peroxidase, superoxide dismutase, and heme oxygenase-1. The same Nrf2 pathway is activated by exercise and intermittent fasting, which helps explain why low-dose ozone is often described as a hormetic stimulus: a controlled, calibrated stress that produces an adaptive biological response.
Three downstream effects are consistently documented in the clinical literature:
Improved Oxygen Delivery
Ozone activates red blood cell metabolism, increasing 2,3-DPG levels and enhancing the release of oxygen to tissues — a meaningful effect in patients with compromised microcirculation.
Immunomodulation
At appropriate concentrations, ozone activates white blood cell signaling cascades, producing dose-dependent modulation of cytokine profiles — neither purely suppressive nor purely stimulatory, but regulatory.
Antioxidant System Upregulation
Through Nrf2 activation, traditional ozone therapy stimulates the body to produce more of its own antioxidants, rather than simply supplying them exogenously.
A physician’s note: Concentration matters enormously here. The therapeutic range for systemic ozone therapy, as defined by international guidelines including the Madrid Declaration, is 10 to 40 µg/mL. Concentrations above 60 µg/mL carry a real risk of erythrocyte hemolysis and antioxidant depletion. This is not a detail to gloss over; it is the reason physician-supervised dosing is essential. An ozone treatment at the wrong concentration is not simply a less effective treatment — it can be a counterproductive or harmful one.
What Does the Evidence Say?
Ozone IV therapy, specifically MAH, is supported by more than 500 peer-reviewed publications and has been formally designated as an evidence-based systemic ozone application by the International Scientific Committee of Ozone Therapy.
Clinical evidence includes a 2024 prospective randomized controlled trial published in International Immunopharmacology (He et al., Renmin Hospital of Wuhan University), which found that Major Autohemotherapy added to conventional therapy significantly improved pulmonary function, 6-minute walk distance, and immunological parameters in patients with post-acute sequelae of COVID-19.
A retrospective study published in PeerJ documented clinically meaningful improvements in pain, functional status, and sleep quality in fibromyalgia patients following 10 sessions of MAH.
The point is not that traditional ozone therapy is a cure for these conditions. It is that MAH has a documented, peer-reviewed mechanistic basis and an established safety profile, and that this foundation exists in a way that more complex ozone modalities are still building toward. For a broader overview of what the evidence currently supports, see our article on the benefits of ozone therapy.
What Is EBOO Treatment?
EBOO stands for Extracorporeal Blood Oxygenation and Ozonation. It is also referred to in the scientific literature as recirculatory hemoperfusion (RHP) and, because of the semi-permeable membrane at its core, as ozone dialysis. The term “dialysis” in this context refers to the filtration mechanism used, not to kidney replacement therapy; this distinction often causes confusion.
EBOO treatment represents a different engineering approach to ozone delivery, not simply a higher dose of traditional ozone therapy, but a distinct procedure with a different architecture.
How often should I do ozone IV therapy or EBOO treatment?
It depends on your goals, your health needs, and your provider’s recommendations. Some people start with a series of treatments, while others space out each injection or session over time.
How Is EBOO Different From Traditional Ozone?
The most important structural difference is the extracorporeal circuit. Unlike standard ozone therapy, which treats a discrete aliquot of blood and returns it in a single pass, EBOO establishes a continuous closed-loop circuit between the patient’s two arms. Blood is drawn from one arm through an IV, passed through a specialized semi-permeable dialysis filter, where it flows in countercurrent contact with an ozone-oxygen gas mixture, and returned through a second IV in the other arm. This continuous circuit allows a substantially larger volume of blood to be processed within a single session.
Where standard MAH treats approximately 150 to 200 milliliters of blood, EBOO treatment processes between 1.8 and 4.8 liters of blood in one session, a meaningful difference in systemic exposure. Research published in PMC confirmed that the countercurrent ozone dialysis mechanism achieves ozone uptake at least three times higher than any comparable blood-based ozone administration currently available, including 10-pass hyperbaric ozone therapy.
The dialysis filter itself introduces an additional element: the physical filtration of cellular byproducts during the extracorporeal circuit. Foundational EBOO research published in Redox Report documented 4–5-fold increases in thiobarbituric acid reactants following sessions, reflecting the magnitude of oxidative reactant processing occurring during treatment.
| Feature | Traditional IV Ozone (MAH) | EBOO Treatment |
| Blood volume per session | 150–200 mL | 1,800–4,800 mL |
| % of total blood volume | ~3–4% | 36–96% |
| IVs required | 1–2 (bilateral) | 2 |
| Dialysis filter | No | Yes |
| Filtration component | None | Semi-permeable membrane |
| Session duration | 45–60 min | 60–90 min |
| Monitoring required | Standard | Continuous |
| Evidence base | Well-established (500+ studies) | Evolving (mechanistic + early clinical) |
A physician’s note: We want to be precise about the filtration claims circulating in patient-facing content. The physical filtration of byproducts through the EBOO dialysis filter is real and documented. What remains analytically unconfirmed, and we think it is important to say this clearly, is the specific composition of what is filtered. Claims about the precise removal of heavy metals, microplastics, and identified pathogens have not been rigorously validated through formal analytical studies comparing filter contents before and after treatment. The filtration effect is real; the specific marketing claims around what is filtered should be understood as plausible mechanistic hypotheses, not confirmed clinical findings.
What Does the EBOO Evidence Say?
EBOO’s evidence base is younger and more limited than that of traditional ozone therapy. This does not make it clinically valueless; it means the degree of certainty is appropriately lower.
Foundational EBOO research established clinical efficacy in peripheral arterial disease, where outcomes were superior to prostacyclin alone. A 2024 randomized controlled trial examining systemic ozone therapy protocols in Long COVID patients found a 71% response rate versus 45% in controls (p=0.0325). Observational studies examining EBOO in post-viral syndromes report response rates in the 67–82% range, though these studies vary significantly in design rigor, patient selection, and comparator groups.
Animal studies confirmed that EBOO at standard concentrations is well-tolerated, with no appreciable erythrocyte hemolysis and no significant adverse effects across a wide concentration range.
What does not currently exist, and this is a meaningful gap, is a well-designed, prospective, head-to-head comparative trial between MAH and EBOO in matched patient populations. The belief that EBOO offers advantages for higher-burden presentations is biologically plausible, mechanistically grounded, and supported by practitioner clinical experience. It is not yet supported by a level of evidence that would allow confident, protocol-level recommendations.
So, Which One Is Right for a Given Patient?
This is the question patients are actually asking. And the answer is that it depends on a clinical assessment, not a preference for one modality over another.
Traditional Ozone Therapy Is Often Appropriate When:
- The patient is new to oxidative therapies, and clinical tolerance is unknown
- The clinical objective is moderate — supporting immune regulation, reducing inflammatory load, or building adjunctive support into a preventive care plan
- The patient’s presentation is relatively well-managed, and ozone is one component of a broader maintenance protocol
- Venous access is limited, or bilateral IV placement is not feasible
- Cost and scheduling frequency are meaningful considerations
Standard ozone treatment, when properly dosed and appropriately indicated, can be performed 2–3 times weekly and fits naturally into an ongoing care plan that includes other modalities.
EBOO Treatment Is Often Considered When:
- The patient has a higher inflammatory or toxic burden — chronic Lyme disease, mold-related illness, complex autoimmune presentations, or persistent post-viral syndromes with multi-system involvement
- Prior rounds of standard ozone therapy have reached a clinical plateau, and a more intensive intervention is being evaluated
- The patient has adequate venous access for bilateral IVs and can tolerate a more procedurally intensive session
- The treating physician has determined that the high-volume, high-uptake characteristics of EBOO are mechanistically appropriate for the clinical problem at hand
EBOO treatment is typically spaced at least one to two weeks apart between sessions, reflecting the intensity of the systemic exposure involved.
A physician’s note: We think about this the way we think about any tiered intervention decision: the more intensive option is not the better one by default. It is the one that matches the physiological demand of the clinical problem. A broadly healthy patient with moderate inflammation does not need EBOO any more than a patient with a mild sinus infection needs intravenous antibiotics. The intensity of the intervention should be calibrated to the severity and complexity of the clinical picture — and that calibration requires a physician who knows the patient well.
What is the cost of EBOO treatment?
The cost of an EBOO session can vary based on the clinic, location, and treatment plan. It is best to ask your provider for exact pricing and what is included, such as monitoring, filtration, and how they introduce ozone during the session.
Common Questions, Answered Precisely
Is EBOO the same as hyperbaric oxygen therapy?
No. Hyperbaric oxygen therapy (HBOT) involves breathing concentrated oxygen in a pressurized chamber. EBOO involves extracorporeal blood ozonation through a dialysis filter. Both influence oxygenation, but through entirely different mechanisms and clinical pathways. They are not interchangeable and are occasionally used as complementary interventions.
Does the EBOO dialysis filter perform dialysis?
The dialysis filter is used for its semi-permeable membrane properties, allowing countercurrent gas exchange between ozone and blood, not for kidney replacement. EBOO is not performing renal dialysis, despite using similar membrane technology. This is a common source of patient confusion.
Can standard ozone therapy and EBOO be combined in a care plan?
Yes. Many patients begin with traditional ozone therapy to establish clinical tolerance and baseline response, and transition to EBOO when clinical indicators support a more intensive intervention. In some protocols, standard ozone infusion sessions are interspersed between EBOO treatments as maintenance. The sequencing and structure of any such plan should be determined by the treating physician based on the patient’s specific response.
How These Therapies Fit at Elite Medical Associates
At EMA, ozone-based therapies are considered adjunctive interventions — one category of tools within a physician-designed care plan, not the entry point into care.
Before any recommendation involving these therapies is made, a patient at EMA has undergone a comprehensive clinical evaluation with detailed history, advanced laboratory assessment including inflammatory markers and oxidative stress indicators, evaluation of cardiometabolic and metabolic status as relevant, and a longitudinal treatment plan that establishes the primary therapeutic framework.
Ozone therapy is considered specifically for patients with chronic inflammatory presentations, post-viral syndromes with persistent immune dysregulation, or complex conditions where oxidative modulation has a mechanistically sound role to play — and only after foundational lifestyle and evidence-based interventions are in place.
These are not therapies we offer because they are popular. They are therapies we consider because, for appropriately selected patients, the biology is coherent and the clinical evidence is meaningful for their wellness. The distinction matters.
A Note on What You May Have Read Elsewhere
Much of the content comparing traditional ozone therapy and EBOO treatment online is written from a commercial perspective — by clinics that offer one or both therapies and have a financial interest in presenting them favorably. That content often makes confident claims about EBOO’s superiority, uses vivid but unscientific imagery, and omits the evidence limitations that an honest clinical assessment would require.
We understand why that content exists. We also think our patients deserve better.
The science underlying both of these therapies is real and increasingly well-characterized in the peer-reviewed literature. The evidence gaps are equally real. At Elite Medical Associates, our obligation is to present both with equal honesty, because the physician-patient relationship we are built to protect requires nothing less.
If you are considering a consultation to discuss whether either form of ozone therapy might be appropriate for your clinical situation, we encourage you to come prepared with questions. The right entry point for that conversation is a thorough evaluation, not a preference for a particular procedure.
This article is for educational purposes only. It does not constitute medical advice, a treatment recommendation, or a diagnosis. All clinical decisions at Elite Medical Associates are made through individualized physician evaluation.